Home › Funds › EULAV Asset Management › MDGL

EULAV Asset Management position in MDGL

MADRIGAL PHARMACEUTICALS INC · Health Care

EULAV Asset Management reported holding 51,000 shares of MDGL (MADRIGAL PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$25.7M, representing 0.93% of its reported portfolio and ranking #38 among its reported holdings. EULAV Asset Management has disclosed MDGL holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)51.00K sh
Reported value held$25.70M
Portfolio Weight0.93%
First reportedQ4 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How EULAV Asset Management's MDGL position evolved

EULAV Asset Management first disclosed a stake in MDGL in Q4 2023 at 13,000 shares (US$3.0M). The position peaked in Q4 2025 at 49,000 shares, worth US$28.5M. Across 12 filings, EULAV Asset Management increased the stake 3 time(s), trimmed it 4 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 51,000 shares valued at US$25.7M — a reduction of -1,000 shares quarter over quarter.. Notable position changes include a 210% increase in Q2 2025 (shares rose 52% over the following quarter), a 65% increase in Q3 2025 (shares rose 27% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 13.00K $3.01M New
Q1 2024 11.00K $2.94M Reduce
Q2 2024 10.00K $2.80M Reduce
Q3 2024 10.00K $2.12M Hold
Q4 2024 10.00K $3.09M Hold
Q1 2025 10.00K $3.31M Hold
Q2 2025 31.00K $9.38M Add
Q3 2025 51.00K $23.39M Add
Q4 2025 49.00K $28.53M Reduce
Q1 2026 49.00K $25.65M Hold
Q2 2026 52.00K $27.92M Add
Q3 2026 51.00K $25.70M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MDGL and 13F data

MDGL (MADRIGAL PHARMACEUTICALS INC) is a Health Care company. 45 other funds we track also report a position in MDGL — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.15B), RTW INVESTMENTS, LP (US$1.07B), Janus Henderson Group (US$1.05B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MDGL

All MDGL fund holders →

FAQ

How long has EULAV Asset Management held MDGL?

EULAV Asset Management has disclosed MDGL holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is EULAV Asset Management's current position in MDGL?

As of Q3 2026, EULAV Asset Management holds 51.00K shares of MDGL (MADRIGAL PHARMACEUTICALS INC), valued at $25.70M, representing 0.93% of its reported portfolio and ranking #38.

Has EULAV Asset Management been buying or selling MDGL?

In the latest 13F filing (Q3 2026), EULAV Asset Management reduced its position in MDGL. The position peaked in Q4 2025 at 49.00K shares.

Which other funds hold MDGL?

Other major institutional holders of MDGL include BAKER BROS. ADVISORS LP, RTW INVESTMENTS, LP, Janus Henderson Group, among 45 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.